The US military has developed a vaccine that it believes could offer protection against all variants of COVID-19.
The Walter Reed Army Institute of Research (WRAIR) developed a 24-sided object to which it attached various protein peaks from coronavirus variants. The vaccine has completed Phase 1 trials, but researchers have yet to test it against the omicron variant, an army spokesperson told Fox News.
Researchers received a sample in early 2020 and focused their efforts on developing a vaccine that would work against potential variants. Two years later, the first results show the promise.
Phase 1 human trials began in April 2021. Scientists have hailed the initial data as encouraging and will release final results from the Phase 1 study once the analysis is complete.
COVID-19: KEY STEPS TO TAKE PLACE IF YOU ARE POSITIVE
The theory behind the development of the Spike Ferritin Nanoparticle Platform (SpFN) vaccine postulates that introducing multiple copies of advanced proteins in an “orderly fashion” may be essential to create a “powerful and broad response”.
“This vaccine stands out in the COVID-19 vaccine landscape,” said Dr. Kayvon Modjarrad, director of Emerging Infectious Diseases Brance at WRAIR. “The repetitive and orderly display of the coronavirus spike protein on a multi-sided nanoparticle can boost immunity in a way that translates into much broader protection.”
COVID-19: AUSTRIA ADDS NEW YEAR’S EVENING RESTRICTIONS
Preclinical studies published in Science Translational Medicine indicate protection against the original strain of COVID-19 as well as variants that emerged from the original 2002 SARS-CoV-1 virus.
“It’s very exciting to get there for our whole team and I think for the whole army too,” Modjarrad said. Defenseone. “With Omicron, there is no way to really escape this virus. You will not be able to avoid it. So I think very soon the whole world will be vaccinated or will have been infected.”
COVID-19 PANDEMIC: CHINA PROBLEMS THE LOCKOUT OF 13 MILLION PEOPLE
One of the main points of interest is how the vaccine interacts with people who have already been vaccinated or who have had a previous infection.
WRAIR will work with a currently unnamed industry partner for a potential larger rollout, but that rollout is unlikely to happen for another year, Dr Marty Makary told Fox News host Shannon Bream.
CLICK HERE TO GET THE FOX NEWS APP
“You get a lot of different levels of immunity, not just against the spike protein,” Makary explained. “It’s in phase one clinical trials. They just announced the results. So it’s about a year to be there.”
Jennifer Griffin of Fox News contributed to this report.